hnRNP A/B Inhibitors

The chemical class of hnRNP A/B Inhibitors encompasses a range of compounds primarily targeting RNA splicing and processing mechanisms, indirectly influencing the function of hnRNP A/B proteins. These proteins play a critical role in RNA metabolism, including pre-mRNA splicing, polyadenylation, and nuclear export. The inhibitors listed are not directly targeting hnRNP A/B but rather the processes and pathways in which these proteins are involved.

Compounds like Pladienolide B, Meayamycin B, Sudemycin D6, FR901464, E7107, Spliceostatin A, Isoginkgetin, Herboxidiene, and Thailanstatin A directly target the spliceosome or components of the splicing machinery. By disrupting the normal splicing process, these inhibitors can potentially alter the function of hnRNP A/B, which are integral to the assembly and regulation of the spliceosomal complex. Indisulam and other carbonic anhydrase inhibitors also have been shown to influence RNA splicing, further indicating the potential of these compounds to indirectly modulate hnRNP A/B activity. Additionally, compounds like GEX1A and Senaparib, which target tyrosine kinase signaling and PARP, respectively, represent a broader approach to influencing hnRNP A/B function. By modulating signaling pathways and DNA repair mechanisms, these inhibitors can indirectly affect the cellular environment and processes in which hnRNP A/B are involved.